Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment
Author:
Ayers Kristin L12, Glicksberg Benjamin S1, Garfield Alastair S3, Longerich Simonne4, White Joseph A4, Yang Pengwei4, Du Lei4, Chittenden Thomas W4, Gulcher Jeffery R4, Roy Sophie3, Fiedorek Fred3, Gottesdiener Keith3, Cohen Sarah5, North Kari E6, Schadt Eric E12, Li Shuyu D12, Chen Rong12, Van der Ploeg Lex H T3
Affiliation:
1. Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York 2. Sema4, Stamford, Connecticut 3. Rhythm Pharmaceuticals, Boston, Massachusetts 4. WuXiNextCode, Cambridge, Massachusetts 5. EpidStat Institute, Ann Arbor, Michigan 6. University of North Carolina, Chapel Hill, North Carolina
Abstract
AbstractContextThe hypothalamic melanocortin 4 receptor (MC4R) pathway serves a critical role in regulating body weight. Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), orMC4R genes, have been shown to cause early-onset severe obesity.MethodsThrough a comprehensive epidemiological analysis of known and predicted LoF variants in thePOMC, PCSK1, andLEPR genes, we sought to estimate the number of US individuals with biallelic MC4R pathway LoF variants.ResultsWe predict ~650α-melanocyte-stimulating hormone (MSH)/POMC, 8500PCSK1, and 3600LEPR homozygous and compound heterozygous individuals in the United States, cumulatively enumerating >12,800 MC4R pathway–deficient obese patients. Few of these variants have been genetically diagnosed to date. These estimates increase when we include a small subset of less rare variants:β-MSH/POMC,PCSK1 N221D, and aPCSK1 LoF variant (T640A). To further define the MC4R pathway and its potential impact on obesity, we tested associations between body mass index (BMI) and LoF mutation burden in thePOMC, PCSK1, andLEPR genes in various populations. We show that the cumulative allele burden in individuals with two or more LoF alleles in one or more genes in the MC4R pathway are predisposed to a higher BMI than noncarriers or heterozygous LoF carriers with a defect in only one gene.ConclusionsOur analysis represents a genetically rationalized study of the hypothalamic MC4R pathway aimed at genetic patient stratification to determine which obese subpopulations should be studied to elucidate MC4R agonist (e.g., setmelanotide) treatment responsiveness.
Funder
Icahn School Medicine at Mount Sinai Sema 4 Rhythm Pharmaceuticals. NIH
Publisher
The Endocrine Society
Subject
Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism
Reference53 articles.
1. Kühnen P ,ClémentK,Poitou-BernertC,FiedorekF,Van Der PloegLH,ConnorsH,GottesdienerK,FarooqiS,WiegandS,GrütersA,KrudeH. Proof of concept for treatment of a second rare genetic disorder of the leptin-melanocortin pathway: successful therapy of extreme obesity in a leptin-receptor (LepR) deficient patient with setmelanotide. Available at:www.rhythmtx.com/wp-content/uploads/2017/03/2017-11-ObesityWeek-Rhythm-Kuhnen.pdf. Accessed 16 May 2018. 2. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist;Kühnen;N Engl J Med,2016 3. Evaluation of a melanocortin-4 receptor (MC4R) agonist (setmelanotide) in MC4R deficiency;Collet;Mol Metab,2017 4. Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity;Farooqi;Nat Clin Pract Endocrinol Metab,2008 5. The genetic contribution to non-syndromic human obesity;Walley;Nat Rev Genet,2009
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|